Procyon Advisors LLC cut its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 18.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,198 shares of the company’s stock after selling 2,574 shares during the period. Procyon Advisors LLC’s holdings in Kenvue were worth $269,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Davis Capital Management boosted its stake in shares of Kenvue by 6.5% in the first quarter. Davis Capital Management now owns 35,022 shares of the company’s stock valued at $840,000 after purchasing an additional 2,145 shares during the period. Northwest Financial Advisors purchased a new position in shares of Kenvue in the first quarter valued at approximately $220,000. Vest Financial LLC boosted its stake in shares of Kenvue by 6.8% in the first quarter. Vest Financial LLC now owns 2,638,279 shares of the company’s stock valued at $63,266,000 after purchasing an additional 167,265 shares during the period. LS Investment Advisors LLC boosted its stake in shares of Kenvue by 2.3% in the first quarter. LS Investment Advisors LLC now owns 52,450 shares of the company’s stock valued at $1,258,000 after purchasing an additional 1,155 shares during the period. Finally, HF Advisory Group LLC boosted its stake in shares of Kenvue by 8.0% in the first quarter. HF Advisory Group LLC now owns 122,888 shares of the company’s stock valued at $2,947,000 after purchasing an additional 9,150 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Kenvue Price Performance
NYSE KVUE opened at $21.30 on Tuesday. The stock’s 50-day moving average price is $23.12 and its two-hundred day moving average price is $22.57. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market cap of $40.87 billion, a PE ratio of 40.19, a PEG ratio of 2.62 and a beta of 0.98. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $25.17.
Kenvue (NYSE:KVUE – Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. During the same quarter in the previous year, the business posted $0.28 EPS. The business’s revenue for the quarter was down 3.9% on a year-over-year basis. On average, analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.85%. Kenvue’s dividend payout ratio is 149.09%.
Wall Street Analysts Forecast Growth
KVUE has been the subject of a number of recent research reports. Piper Sandler lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research note on Monday, February 24th. Evercore ISI assumed coverage on shares of Kenvue in a report on Monday, March 24th. They set an “in-line” rating and a $25.00 price objective on the stock. Canaccord Genuity Group raised their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Redburn Atlantic assumed coverage on shares of Kenvue in a report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price objective on the stock. Finally, Citigroup raised their price objective on shares of Kenvue from $22.00 to $24.50 and gave the stock a “neutral” rating in a report on Friday, May 9th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $25.33.
Read Our Latest Report on Kenvue
About Kenvue
(Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Kenvue and related companies with MarketBeat.com’s FREE daily email newsletter.
